Most people will ignore this.
Until it's too late.
$STRX has pulled back directly into the 200 EMA—a level that has historically sparked major reversals.
One bounce could change the entire market structure.
Watching closely.
Watching $STRX closely.
Price has corrected sharply and is now testing the 200 EMA-a level that has historically acted as strong trend support.
A successful bounce could ignite the next leg higher.
Lose it, and momentum shifts to the bears.
Choose your side.
I believe $HIMS could be one of the defining healthcare winners of this decade.
Here's why 🧵
Strong consumer brand.
Expanding into multiple treatment categories.
Improving operating leverage.
Huge addressable market.
The opportunity is much bigger than many investors realize.
$BYND
Reported short interest dropped another ~7M shares as of 6/15.
The real story is potential synthetic exposure.
If estimates suggesting 300%+ effective short exposure are even remotely accurate...
This could become one of the most explosive squeeze setups on the market.
The market rewarded $HIMS with a 34.7% rally.
Now comes the real test.
✔ FDA peptide committee
✔ Q2 earnings
✔ Updated guidance
Good companies don't stop moving because they're up 30%.
They keep moving if the fundamentals keep improving.
I'm staying bullish on $HIMS.
The #okstate#wheat variety trial on the OSU Southwest Research Center is going to be a fine example of how bad early stripe rust can limit yield potential. Most have significant early damage, but some eventually showed tolerance by having a healthier flagleaf.
Stillwater, we are coming in Full Tilt at @TumbleweedOK Saturday. It’s the biggest party of the year, get your tickets before it’s too late!
https://t.co/A04rbVjOL4